The Centers for Medicare and Medicaid Services (CMS) projects Medicare home health spending in the US will grow at an 8-year (2023-2031) CAGR of +8.6% compared to +7.4% for hospital expenditures. These projections help validate that healthcare services are shifting to the home care setting. The migration is driven by efforts to reduce costs, improve access and enhance the quality of care. Policymakers continue to manipulate reimbursement formulas to incentivize change. CMS recently released the CY 2024 Home Health Prospective Payment System (PPS) Proposed Rule that includes reimbursement policy revisions that could potentially increase the utilization of disposable negative pressure wound therapy (dNPWT) in the home health setting. This free downloadable article highlights:

• The Trajectory of dNPWT,
• Historical Challenges Associated with the Uptake in the Home Setting
• Incremental Policy Efforts Designed to Mitigate Those Challenges
• Billing Complexity Stalling Growth
• Incremental Changes Show Progress
• Impact of Proposed Policy Changes. 

With the establishment of a separate payment for the dNPWT and the relatively simpler billing processes, the proposed CMS changes are a net positive for manufacturers treating wounds in the home health setting. However, given the growing competition ...

To download the complete "CMS Proposed Rule Incentivizes Home Use of Disposable NPWT" perspective article by Terry Hayslett, SmartTRAK Senior Analyst, Advanced Wound Care, just click the button below.

• Complete Q123 Trauma Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Trauma Companies' News, Revenues, Data, Charts and Market Shares
• IM Nailing Closes the Quarter on High with Solid Returns
• New Regulatory Clearances Propel the Pediatric Trauma Segment:
  • OrthoPediatrics
  • NuVasive Specialized Orthopedics, Inc.
  • Wishbone Medical
• Q123 Trauma Regulatory Highlights

During Q1, the Pediatric Trauma segment experienced a notable surge in regulatory clearances, indicating forthcoming product launches aimed at bolstering the segment's growth. These approvals signal  ...

Read the entire Q123 Trauma Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

SmartTRAK’s survey of interventional pain physicians reveals valuable insights into current and future trends in interventional pain management and peripheral nerve stimulation (PNS)

SmartTRAK recently conducted a survey of 30 interventional pain physicians, including 18 doctors who perform PNS, to gain insight into the current state of interventional pain management and identify future trends in the field. This includes physician use of SCS, DRG Stimulation, short- and long-term PNS, RFA, TDD, Regenerative Medicine injections and MIS spine procedures, with an emphasis on PNS companies and technologies.

This comprehensive study sheds light on procedure trends, preferred treatment approaches, physicians' perspectives on PNS and more!

Key questions include:

• What interventional pain procedures are expected to grow the most in the next 12-24 months?
• What minimally invasive spine procedures do physicians think will increase the most in the next few years?
• What are expected procedure volumes for Regenerative Medicine injections?
• What are the most preferred treatment approaches for different chronic pain conditions?
• What are physicians' impressions of the different PNS technologies/brands?
• What are the top targets for PNS and what's driving and limiting physician adoption of PNS?
• What technology improvements do physicians want to see in PNS devices?

Click the button below if you are interested in purchasing SmartTRAK’s Interventional Pain Management and Peripheral Nerve Stimulation Survey. Be The Expert with the latest insights and trends in the field and equip yourself with valuable knowledge. Click Now!

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 Spine Market Recap* are:

• Complete Q123 Spine Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Spine Companies' News, Revenues, Data, Charts and Market Shares
• Top Players' Performance
  •  JNJ/DePuy Synthes
  • Globus 
  • NuVasive 
  • Stryker
• Q123 Spine Trends
  • M&A Activity
  • New Products
  • Reimbursement Dynamics
• Regulatory Highlights
• Europe Regulatory Updates
• Clinical Study Progress

Orthofix and SeaSpine announced the completion of its merger in Q123 in which SeaSpine became a wholly owned subsidiary of Orthofix. In a recent note, Canaccord Genuity highlighted SeaSpine, 7D Surgical and Simplify as the most notable of the recent spine acquisitions. SmartTRAK agrees and notes that ...

Read the entire Q123 Spine Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

Discover how Europe is transforming into a hotbed of innovation for chronic wound care through the breakthrough technology of cold plasma therapy. As the global focus on chronic wounds intensifies, European markets are witnessing a surge in new technologies that offer promising solutions. From smaller, portable devices to collaborative research efforts, this article highlights the rise of cold plasma therapy and its potential to revolutionize wound care. Download the article to further explore these, and other, key points:

• Europe's lower revenue levels for advanced wound therapies compared to the US present an opportunity for new technologies to thrive.
• Cold plasma therapy, utilizing low-temperature atmospheric pressure plasmas, demonstrates impressive benefits in treating chronic wounds, including bacterial inactivation and enhanced healing.
• Recent advancements have led to the development of smaller and more portable cold plasma devices, expanding treatment options beyond hospitals to ambulatory settings and even patients' homes.
• Swiss company ActivCell Group Ag, German companies neoplas med GmbH and Plasmacure BV and Dutch company Terraplasma Medical GmbH are among the pioneering companies offering innovative cold plasma devices.
• The future of cold plasma therapy depends on the willingness of companies to collaborate, navigate regulatory challenges, and establish a distinct market presence.
• While European advancements in cold plasma therapy are promising, the highly competitive US market remains a long-term goal for most companies, necessitating FDA approval and strategic partnerships.
• The rapid growth of topical oxygen therapy in the US, driven by initiatives like the Veterans Association and state-level Medicaid approvals, could potentially outpace European progress once FDA approval is obtained.

The full article delves into the transformative potential of cold plasma therapy in chronic wound care. Explore the advancements, collaborations and challenges that shape Europe's emerging market and its race against the US in revolutionizing wound treatment. Just click the button below to download the complete "EWMA 2023 - Cold Plasma Poised for Growth in Europe" article by Kris Flinn, SmartTRAK Senior Analyst - Wound.

Soft Tissue Fixation Rebounds in Q123 To Start the Year In a Positive Direction

In Q1, the STF market experienced notable growth, primarily driven by several factors, including an increase in elective procedures, a decrease in the effects of supply chain issues and increased growth over a sluggish Q122. Overall, these factors collectively propelled the STF market to exhibit robust growth during the first quarter.

Among the many topics covered in detail inSmartTRAK's comprehensiveQ123 Soft Tissue Fixation Market Recap* are:

• Complete Q123 Soft Tissue Fixation Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All STF Companies' News, Revenues, Data, Charts and Market Shares
• Headwinds and Tailwinds
• Top Competitor Results & Highlights
• Q123 Clinical/Regulatory Highlights

In the first quarter of 2023, the orthopedic ambulatory surgical center (ASC) market in the US experienced positive developments. The market witnessed significant growth in personnel, contracts and portfolio expansion within Sports Medicine companies. In their Q1 earnings call, Zimmer Biomet* COO Ivan Tornos commented that ...

In addition to product innovation and increasing adoption, the Spine Enabling Technology market is rapidly evolving due to mergers and acquisitions.

The Q123 WW Spine Enabling Tech Market was up +12.6% YoY, according to SmartTRAK Financial Dashboard. Medtronic (MDT) remained the market leader with 54.9% share, followed by Globus Medical (GMED) and other enabling tech competitors like Brainlab and Stryker (SYK). For detailed Q123 revenues and shares by company in the US, EU and ROW, see SmartTRAK Spine Enabling Tech Financial Dashboard*.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 US Spine Enabling Technology Market Recap* are:

• Complete Q123 Spine Enabling Tech Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Companies' News, Revenues, Data, Charts and Market Shares
• Mergers and Acquisitions Changing the Spine Enabling Technology Landscape
• New Spine Robots on the Horizon
• Milestones in Augmented Reality
• Q123 Regulatory Highlights

In February 2023, GMED announced it entered into a definitive agreement to combine in an all-stock transaction with NuVasive (NUVA). The transaction is expected to close mid-2023 subject to shareholder and regulatory agency approvals, which will make the combined company the ...

Read the entire Q123 Spine Enabling Tech Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.